In a mouse model of cervical carcinogenesis, it was shown that targeting in particular tumor-associated fibroblasts with the PDGFR inhibitor imatinib mesylate, results in slowed progression of premalignant lesions and impaired growth of invasive carcinoma [72]. This evidence concerns the gene PDGFRB and neoplasm.